Should Alkermes’ (ALKS) New Phase 3 Narcolepsy Program Reshape Its Sleep-Disorder Investment Narrative?

• In early April 2026, Alkermes plc announced that it had initiated the Brilliance phase 3 program to evaluate its oral orexin 2 receptor agonist alixorexton in adults with narcolepsy type 1 and type 2 across three 12-week, randomized, double-blind, placebo-controlled studies.
• The launch of these global Brilliance Studies marks a significant step in advancing orexin-targeted therapies, potentially broadening Alkermes’ footprint in sleep-wake disorders if outcomes are favorable.
• With phase 3 Brilliance Studies now underway for alixorexton, we’ll examine how this late-stage sleep pipeline asset influences Alkermes’ investment narrative.

Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

Alkermes Investment Narrative Recap

To own Alkermes, you need to believe its focused CNS portfolio can fund and support a successful transition into orexin-based sleep medicines, with alixorexton as a key late-stage asset. The Brilliance phase 3 launch is important for that story, but it does not change that the most immediate swing factor is whether late-stage data are positive enough to justify rising R&D spend, while ongoing reliance on a few core products remains a central business risk.

The most relevant recent announcement in this context is the US FDA’s Breakthrough Therapy designation for alixorexton in narcolepsy type 1, granted in January 2026. That regulatory support, combined with the new Brilliance phase 3 program, frames alixorexton as a central catalyst whose outcomes could either reinforce or challenge the consensus view on Alkermes’ longer term earnings power and justify the current investment in its orexin pipeline.

Yet, against this potential, investors should be aware that rising R&D for alixorexton could weigh on margins if...

Read the full narrative on Alkermes (it's free!)

Alkermes' narrative projects $2.1 billion revenue and $245.7 million earnings by 2029. This requires 11.7% yearly revenue growth and a modest $4.0 million earnings increase from $241.7 million today.

Uncover how Alkermes' forecasts yield a $43.71 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming about US$1.7 billion in 2028 revenue and US$276.3 million in earnings, so if Brilliance results shift views on alixorexton’s concentration risk, those upbeat forecasts could look either too cautious or too generous depending on how you see the same information.

Explore 5 other fair value estimates on Alkermes - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alkermes research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com